{"id":"continuous-heparin-infusion","safety":{"commonSideEffects":[{"rate":"1-10%","effect":"Bleeding"},{"rate":"0.5-3%","effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":"0.5-2%","effect":"Thrombosis"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Alopecia (with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL4650299","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Heparin works by binding to antithrombin III, which then inactivates thrombin (Factor IIa) and Factor Xa, thereby interrupting the coagulation cascade. Continuous intravenous infusion maintains steady anticoagulant levels in the bloodstream, preventing clot formation and extension in acute thrombotic conditions.","oneSentence":"Heparin is an anticoagulant that inhibits multiple clotting factors to prevent thrombus formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:29.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)"},{"name":"Acute coronary syndrome"},{"name":"Atrial fibrillation with thromboembolism risk"},{"name":"Prevention of thrombosis during cardiac surgery and extracorporeal circulation"}]},"trialDetails":[{"nctId":"NCT06096064","phase":"","title":"Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2022-10-31","conditions":"Unfractionated Heparin","enrollment":100},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT05286814","phase":"PHASE2","title":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-24","conditions":"Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer","enrollment":70},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT06080074","phase":"PHASE2","title":"Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-04-15","conditions":"Heart Failure, Cardiogenic Shock, Congenital Heart Disease","enrollment":50},{"nctId":"NCT07361081","phase":"","title":"Protocol-Driven Continuous Infusion Versus Intermittent Bolus Heparin During Atrial Fibrillation Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation (AF), Ablation","enrollment":300},{"nctId":"NCT07285603","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229","status":"COMPLETED","sponsor":"Matisse Pharmaceuticals","startDate":"2024-11-21","conditions":"Healthy Subjects","enrollment":15},{"nctId":"NCT06150742","phase":"NA","title":"Nafamostat Efficacy in Phase 3 Registrational CRRT Study","status":"RECRUITING","sponsor":"Talphera, Inc","startDate":"2024-08-15","conditions":"Acute Kidney Injury","enrollment":70},{"nctId":"NCT07214103","phase":"PHASE2","title":"Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-03-01","conditions":"Septic Shock, Coagulopathy","enrollment":120},{"nctId":"NCT06424015","phase":"NA","title":"Insulin and Insulin Pulses During Fasting","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-09-15","conditions":"PreDiabetes","enrollment":60},{"nctId":"NCT05984537","phase":"PHASE4","title":"A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2023-07-01","conditions":"Coronary Microvascular Dysfunction","enrollment":70},{"nctId":"NCT06712004","phase":"PHASE2","title":"A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-02-10","conditions":"Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction","enrollment":40},{"nctId":"NCT04997265","phase":"NA","title":"Strategies for Anticoagulation During Venovenous ECMO","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-12","conditions":"Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism","enrollment":26},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT04251715","phase":"PHASE2","title":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-04-28","conditions":"Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":5},{"nctId":"NCT05208112","phase":"PHASE1","title":"Intravenously Administered M6229 in Critically Ill Sepsis Patients","status":"COMPLETED","sponsor":"A.P.J. Vlaar","startDate":"2022-04-05","conditions":"Sepsis, Septic Shock, Critical Illness","enrollment":10},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT06646328","phase":"PHASE4","title":"Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.","status":"TERMINATED","sponsor":"Fernando Sanchez","startDate":"2018-06-09","conditions":"Acute Kidney Injury","enrollment":20},{"nctId":"NCT06622564","phase":"PHASE3","title":"Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-01-01","conditions":"Bleeding, Surgical Blood Loss, Seizures","enrollment":40},{"nctId":"NCT05226442","phase":"PHASE2, PHASE3","title":"Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2021-12-01","conditions":"Extracorporeal Membrane Oxygenation Complication, Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT06487052","phase":"NA","title":"Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients","status":"RECRUITING","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2024-01-10","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT05540834","phase":"PHASE2","title":"Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure","status":"RECRUITING","sponsor":"South West Sydney Local Health District","startDate":"2022-05-18","conditions":"Acute Respiratory Failure, Hypercoagulability, Fibrinolysis Shutdown","enrollment":70},{"nctId":"NCT04571645","phase":"PHASE3","title":"Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2021-04-30","conditions":"Acute Myeloid Leukemia","enrollment":9},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT02873338","phase":"PHASE2","title":"Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT02879201","phase":"NA","title":"Continuous Venovenous Hemodiafiltration Versus Sustained Low-efficiency Hemodialysis for Critically Ill Patients With Acute Kidney Injury in Intensive Care Unit","status":"COMPLETED","sponsor":"Bangkok Metropolitan Administration Medical College and Vajira Hospital","startDate":"2009-01","conditions":"Acute Kidney Injury","enrollment":27},{"nctId":"NCT01482455","phase":"NA","title":"Fat and Transcapillary Insulin Transport","status":"COMPLETED","sponsor":"German Diabetes Center","startDate":"2011-12","conditions":"Lipid-induced Insulin Resistance","enrollment":8},{"nctId":"NCT02474212","phase":"PHASE4","title":": Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2016-05","conditions":"Venous Thromboembolism, Pulmonary Embolism, Thromboprophylaxis","enrollment":85},{"nctId":"NCT05827120","phase":"","title":"Endovascular Therapy in Patients With Acute Deep Vein Thrombosis","status":"COMPLETED","sponsor":"National Institute of Cardiovascular Diseases, Slovakia","startDate":"2021-03-23","conditions":"Acute Deep Venous Thrombosis","enrollment":110},{"nctId":"NCT02923115","phase":"PHASE1, PHASE2","title":"Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-06-23","conditions":"Pulmonary Embolism, Thrombotic Disease","enrollment":134},{"nctId":"NCT04861922","phase":"PHASE3","title":"Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2021-05-11","conditions":"Sepsis, Gram-Negative Bacterial Infections, Heparin","enrollment":100},{"nctId":"NCT05742126","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dosed of HSK36273 in Healthy Volunteers","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2022-04-11","conditions":"Healthy","enrollment":54},{"nctId":"NCT02056782","phase":"PHASE1","title":"A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2013-12","conditions":"Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT03318393","phase":"PHASE4","title":"Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-03-25","conditions":"Extracorporeal Membrane Oxygenation Complication, Pediatric ALL, Anticoagulants","enrollment":30},{"nctId":"NCT05493163","phase":"PHASE4","title":"Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism","status":"RECRUITING","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2022-10-19","conditions":"Pulmonary Embolism","enrollment":558},{"nctId":"NCT05602129","phase":"PHASE2","title":"A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects","status":"UNKNOWN","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2022-11","conditions":"Renal Replacement Therapy","enrollment":156},{"nctId":"NCT04767113","phase":"NA","title":"Continuous Heparin Infusion to Prevent Catheter-related Thrombosis","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-03-01","conditions":"Cardiac Surgery, Central Venous Catheter Thrombosis, Heparin","enrollment":35},{"nctId":"NCT04389840","phase":"PHASE2, PHASE3","title":"Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2020-07-08","conditions":"Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","enrollment":27},{"nctId":"NCT01525069","phase":"PHASE1","title":"Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-04-03","conditions":"Cholangiocarcinoma, Liver Neoplasms","enrollment":27},{"nctId":"NCT01461915","phase":"PHASE2","title":"Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2011-11","conditions":"Metastatic Pancreatic Cancer","enrollment":60},{"nctId":"NCT02501434","phase":"PHASE2","title":"Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin","status":"SUSPENDED","sponsor":"Robert F. James","startDate":"2016-04","conditions":"Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial","enrollment":88},{"nctId":"NCT04357730","phase":"PHASE2","title":"Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2020-05-14","conditions":"Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome","enrollment":50},{"nctId":"NCT00457951","phase":"PHASE2","title":"A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2007-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT04297839","phase":"PHASE3","title":"Evaluation of Regional Anticoagulation With Citrate in Extended Hemodialysis","status":"SUSPENDED","sponsor":"University of Sao Paulo General Hospital","startDate":"2019-02-12","conditions":"Hemodialysis Complication, Acute Kidney Injury, Anticoagulant Toxicity","enrollment":200},{"nctId":"NCT01608906","phase":"NA","title":"Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":"Venous Thrombosis","enrollment":152},{"nctId":"NCT04855890","phase":"NA","title":"HIgh Power Short Duration Radiofrequency Ablation or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation","status":"UNKNOWN","sponsor":"Universitätsklinikum Köln","startDate":"2021-05-01","conditions":"Atrial Fibrillation and Flutter, Atrial Fibrillation, Paroxysmal Atrial Fibrillation","enrollment":170},{"nctId":"NCT00695201","phase":"PHASE1","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":"Colon Cancer, Rectal Cancer","enrollment":52},{"nctId":"NCT04528888","phase":"PHASE3","title":"Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection","status":"UNKNOWN","sponsor":"Massimo Girardis","startDate":"2020-11-25","conditions":"Covid19, SARS-CoV Infection, Pneumonia, Viral","enrollment":210},{"nctId":"NCT04865510","phase":"NA","title":"Citrate Versus Heparin in Continuous Renal Replacement Therapy :","status":"COMPLETED","sponsor":"Bangkok Metropolitan Administration Medical College and Vajira Hospital","startDate":"2019-02-04","conditions":"Acute Kidney Injury, Citrate, Cytokines","enrollment":41},{"nctId":"NCT03854266","phase":"PHASE2","title":"Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2020-03-10","conditions":"Pulmonary Embolism","enrollment":60},{"nctId":"NCT04829552","phase":"","title":"Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units","status":"COMPLETED","sponsor":"Corewell Health East","startDate":"2020-03-10","conditions":"Covid19","enrollment":704},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04042324","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients","status":"COMPLETED","sponsor":"Rockwell Medical Technologies, Inc.","startDate":"2019-09-30","conditions":"End Stage Renal Disease","enrollment":12},{"nctId":"NCT01839487","phase":"PHASE2","title":"PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-05-14","conditions":"Metastatic Pancreatic Cancer","enrollment":279},{"nctId":"NCT03747263","phase":"NA","title":"Individualized Approach vs. Fixed Approach","status":"COMPLETED","sponsor":"University of Luebeck","startDate":"2018-12-01","conditions":"Paroxysmal Atrial Fibrillation","enrollment":100},{"nctId":"NCT04048525","phase":"NA","title":"Cytokine Removal With CVVHD Compared to CVVH","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2013-03-13","conditions":"Cytokine Release Syndrome, Sepsis, AKI","enrollment":40},{"nctId":"NCT04241380","phase":"NA","title":"Anticoagulation Medicine in Surgical Repair for Total Anomalous Pulmonary Venous Connection","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2020-02-20","conditions":"Total Anomalous Pulmonary Venous Connection","enrollment":150},{"nctId":"NCT02995655","phase":"PHASE1","title":"CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-04-07","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML","enrollment":20},{"nctId":"NCT04121611","phase":"NA","title":"Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-10-14","conditions":"Stroke of Basilar Artery, Optical Coherence Tomography, Antithrombotics","enrollment":25},{"nctId":"NCT00603824","phase":"PHASE4","title":"Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)","status":"WITHDRAWN","sponsor":"Methodist Healthcare","startDate":"2008-01","conditions":"Heparin-Induced Thrombocytopenia","enrollment":""},{"nctId":"NCT03965208","phase":"PHASE4","title":"Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation","status":"UNKNOWN","sponsor":"Legacy Health System","startDate":"2019-05-23","conditions":"Extracorporeal Membrane Oxygenation Complication, Anticoagulants","enrollment":34},{"nctId":"NCT01378000","phase":"","title":"Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction","status":"COMPLETED","sponsor":"Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine","startDate":"2009-10","conditions":"Heparin Causing Adverse Effects in Therapeutic Use, Heparin-induced Thrombosis, Acute Cerebral Ischemia","enrollment":480},{"nctId":"NCT00986154","phase":"PHASE3","title":"Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-10","conditions":"Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":8292},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT01318811","phase":"PHASE4","title":"A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2011-03","conditions":"Acute Kidney Injury, Acute Renal Failure, Heart Failure","enrollment":12},{"nctId":"NCT02565147","phase":"PHASE3","title":"Bivalirudin Infusion for Ventricular Infarction Limitation","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2014-12-19","conditions":"Acute Myocardial Infarction","enrollment":78},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT00331162","phase":"PHASE4","title":"Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2005-02","conditions":"Graft Rejection","enrollment":222},{"nctId":"NCT02164097","phase":"PHASE1","title":"ODSH + ICE Chemotherapy in Pediatric Solid Tumors","status":"TERMINATED","sponsor":"New York Medical College","startDate":"2015-01","conditions":"Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma","enrollment":4},{"nctId":"NCT02095509","phase":"PHASE4","title":"Pharmacokinetics of Enoxaparin in Intensive Care Patients","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2014-03","conditions":"Venous Thromboembolism","enrollment":39},{"nctId":"NCT03306836","phase":"NA","title":"Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2016-09","conditions":"Cerebral Aneurysm, Arteriovenous Malformations","enrollment":408},{"nctId":"NCT02707263","phase":"NA","title":"Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2016-03","conditions":"Venous Thromboembolism","enrollment":""},{"nctId":"NCT01076764","phase":"PHASE3","title":"Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-04","conditions":"Acute Coronary Syndrome","enrollment":13220},{"nctId":"NCT01532544","phase":"PHASE2","title":"Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis","status":"TERMINATED","sponsor":"Thrombologic ApS","startDate":"2012-06","conditions":"Pneumonia","enrollment":5},{"nctId":"NCT01935557","phase":"PHASE3","title":"Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation","status":"COMPLETED","sponsor":"Yong Seog Oh","startDate":"2012-12","conditions":"Coagulation; Intravascular","enrollment":296},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT01980316","phase":"PHASE4","title":"Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting","status":"COMPLETED","sponsor":"Xinfeng Liu","startDate":"2010-04","conditions":"CVD","enrollment":114},{"nctId":"NCT02529774","phase":"PHASE2, PHASE3","title":"Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Ye Xu","startDate":"2015-09","conditions":"Resected Liver Metastases From Colorectal Cancer","enrollment":432},{"nctId":"NCT00968565","phase":"EARLY_PHASE1","title":"Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-01","conditions":"Heart Defects, Congenital, Respiratory Insufficiency","enrollment":2},{"nctId":"NCT00271401","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"1996-07","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":2399},{"nctId":"NCT00251771","phase":"NA","title":"Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2006-01","conditions":"Deep Vein Thrombosis","enrollment":209},{"nctId":"NCT01163097","phase":"PHASE1","title":"Study to Characterize the Effect of Heparin on Palifermin Activity","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2010-07","conditions":"Oral Mucositis","enrollment":44},{"nctId":"NCT01839578","phase":"NA","title":"Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2013-05","conditions":"Septic Shock","enrollment":30},{"nctId":"NCT01648036","phase":"PHASE2","title":"Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2012-07","conditions":"Septic Shock","enrollment":76},{"nctId":"NCT02135770","phase":"PHASE3","title":"Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2013-01","conditions":"Severe Sepsis With Septic Shock, Severe Sepsis Without Septic Shock","enrollment":115},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT02159287","phase":"PHASE2","title":"Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke","status":"UNKNOWN","sponsor":"Shiraz University of Medical Sciences","startDate":"2014-01","conditions":"Embolic Stroke","enrollment":80},{"nctId":"NCT00323011","phase":"PHASE2","title":"FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2006-05","conditions":"Colorectal Cancer","enrollment":5},{"nctId":"NCT01626911","phase":"NA","title":"Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis","status":"UNKNOWN","sponsor":"Nanjing University School of Medicine","startDate":"2011-09","conditions":"Acute Pancreatitis","enrollment":60},{"nctId":"NCT00916669","phase":"PHASE2","title":"A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00427310","phase":"PHASE3","title":"Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"1984-03","conditions":"Colorectal Cancer","enrollment":1158},{"nctId":"NCT00798525","phase":"PHASE4","title":"Argatroban Versus Lepirudin in Critically Ill Patients","status":"TERMINATED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2009-01","conditions":"Heparin Induced Thrombocytopenia (HIT)","enrollment":70},{"nctId":"NCT01138683","phase":"PHASE3","title":"Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-02","conditions":"Acute Decompensated Heart Failure","enrollment":1},{"nctId":"NCT00829569","phase":"NA","title":"n-3 Fatty Acid Infusion and Type 2 Diabetes","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2004-01","conditions":"Type 2 Diabetes","enrollment":11},{"nctId":"NCT01351324","phase":"NA","title":"A Study of Different Types of Fatty Acid on Risk Factors for Heart Disease","status":"COMPLETED","sponsor":"University of Reading","startDate":"2009-03","conditions":"Cardiovascular Risk Factors","enrollment":59},{"nctId":"NCT01267487","phase":"PHASE4","title":"Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"SANE-Society of Anesthesiology","startDate":"2009-07","conditions":"Cardiac Surgery, Cardiopulmonary Bypass, Anticoagulation","enrollment":240},{"nctId":"NCT00890214","phase":"PHASE4","title":"Prostacyclin's Effect on Platelet Responsiveness","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2007-09","conditions":"Acute Kidney Failure","enrollment":23},{"nctId":"NCT00796692","phase":"PHASE4","title":"Nadroparin for the Initial Treatment of Pulmonary Thromboembolism","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2002-06","conditions":"Pulmonary Embolism, Thromboembolism, Vascular Diseases","enrollment":274},{"nctId":"NCT00759629","phase":"PHASE4","title":"Beyond 12 Hours Reperfusion AlternatiVe Evaluation Trial","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2001-05","conditions":"Myocardial Infarction","enrollment":365}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":109,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Continuous heparin infusion","genericName":"Continuous heparin infusion","companyName":"Yong Seog Oh","companyId":"yong-seog-oh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Heparin is an anticoagulant that inhibits multiple clotting factors to prevent thrombus formation. Used for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism), Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}